Free Trial
NASDAQ:AURA

Aura Biosciences Q4 2024 Earnings Report

Aura Biosciences logo
$6.03 -0.12 (-1.93%)
As of 10:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aura Biosciences EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Aura Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aura Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 24, 2025
Conference Call Time
10:30AM ET

Upcoming Earnings

Aura Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aura Biosciences Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP
See More Aura Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email.

About Aura Biosciences

Aura Biosciences (NASDAQ:AURA), a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

View Aura Biosciences Profile

More Earnings Resources from MarketBeat